Drug Toxicity is an indication for drug development with over 260 pipeline drugs currently active. According to GlobalData, preregistered drugs for Drug Toxicity have a 77.78% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Drug Toxicity compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Likelihood of Approval Analysis for Drug Toxicity

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Drug Toxicity overview

Drug toxicity’ can be defined as a diverse array of adverse effects which are brought about through drug use at either therapeutic or non-therapeutic doses. Slight symptoms like headaches or nausea, to severe symptoms like coma and convulsions and death. The causes of drug toxicity can be organized in several ways and include mechanism-based (on-target) toxicity, immune hypersensitivity, off-target toxicity, and bioactivation/covalent modification. If the toxicity results from an acute overdose, a person may undergo stomach pumping to remove drugs that have not yet been absorbed. Activated charcoal is another drug toxicity treatment option, used to bind the drug, preventing it from being absorbed into the blood.

For a complete picture of PTSR and LoA scores for drugs in Drug Toxicity, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.